Development of a novel class of hyper-multi-targeted computer-aided CREKA/YIGSR

4^th International Conference on Medicinal Chemistry & Computer Aided Drug Designing

November 02-04, 2015 Atlanta, USA

Ioannis Grigoriadis

Biogenea Pharmaceuticals Ltd, Greece

Scientific Tracks Abstracts: Med chem

Abstract :

Drug discovery and development is an interdisciplinary, expensive and time-consuming process. Scientific advancements during the past two decades have changed the way pharmaceutical research generate novel bioactive molecules. Advances in computational techniques and in parallel hardware support have enabled in silico methods, and in particular structure-based drug design method, to speed up new target selection through the identification of hits to the optimization of lead compounds in the drug discovery process. Glioblastoma multiforme (GBM) is the most aggressive central nervous system (CNS) tumor because of its fast development, poor prognosis, difficult control and terrible mortality. Poor penetration and retention in the glioblastoma parenchyma were crucial challenges in GBM nanomedicine therapy. Here, in Biogenea we have for the first time discovered an in silico high binding free energy affinity value predicted Novel Hyper-Multi-Targeted computer-aided Inhibitor against tumor growth and experimental metastasis related Glioblastoma conserved motif-like peptide domains.These results demonstrate that the VDAC1 treating CLL peptides may assist target-fishing approaches that are currently ubiquitous in cheminformatics and can be essentially viewed as single-label peptidomimetic drug discovery schemes. Here, we have for the first time in silico Development of a novel class of hyper-multi-targeted computer-aided CREKA/YIGSR-peptide mimotopic dual Inhibitor against tumor growth, metastasis related glioblastoma conserved motif-like peptide domains VDAC1-peptide mimetic tubulin targeted HA14-1-based multivalent chemical inhibitorory promising anticancer activities as novel in silico high binding free energy affinity value pro-apoptotic annotated agent for B-cell chronic lymphocytic leukemia.

Biography :

Ioannis Grigoriadis has completed his PharmacistD at the age of 24 years from Aristotle University of Thessaloniki and doctoral studies from University of Ioannina Medical School. He is the scientific director of Biogenea Pharmaceuticals Ltd, a premier biotechnology personalized cancer vaccination service organization. He has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute.

Email: biogeneadrug@gmail.com